Controversial Italian COVID-19 IVDs Tender Must Not Be A Blueprint For The Future, Says Industry

Pooling of diagnostics resources should be preferred in the long-term

Italy must ensure that ongoing efforts to tackle the coronavirus crisis do not rely on single suppliers, the country's medtech industry body said after DiaSorin looked likely to be the sole winner of a major COVID-19 diagnostics tender.

Map_Milan_Covid19

Tackling the coronavirus crisis should be a collaborative effort, the Italian medtech industry body said after DiaSorin SPA looked to be the likely winner of a major COVID-19 diagnostics tender ̶ asserting that the process should not set the pattern for future tenders.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Update: Italy’s IMQ And Belgium’s SGS Named 15th and 16th IVDR Notified Bodies

 

Ireland’s NSAI reinstated under IVD Regulation designation list

Notified Bodies Warn Of Hurdles In The Way Of Their AI Designations

 

Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?

Keeping Germany’s Medtech Industry Apprised, Advised and Incentivized in Turbulent Times

 
• By 

A change of government, hospital reform and a drive towards healthcare digitization are keeping German medtech manufacturers on their toes. Making the MDR more user-friendly and winning support for a medtech strategy are arguably bigger priorities. US export tariffs have also pushed their way onto the agenda. BVMed chief executive Marc-Pierre Möll puts it all into context.

Edwards Mitral Valve Replacement System SAPIEN M3 Receives CE Mark

 

“We believe [the SAPIEN M3] launch alongside PASCAL and EVOQUE will help support the company’s target of $2bn in transcatheter mitral and tricuspid therapies sales by 2030,” noted analysts from Leerink Partners.

More from Geography

Makary Proposes Combined Adverse Event Reporting Systems In Megyn Kelly Interview

 

In discussing FDA’s adverse event monitoring, Makary also seemed to falsely imply the agency did not fully investigate the myocarditis signal with COVID-19 vaccines.

Upcoming CMS Meetings Address Tremor-Control Devices, Lab Test Reimbursement

 
• By 

The US Medicare agency will hold three public meetings in June and July addressing tremor treatment devices and clinical diagnostic lab tests. The first meeting on June 25 will focus on endpoints for Parkinson’s device trials, while subsequent meetings will address payment rates and codes for laboratory tests.

Trump’s Preliminary 2026 HHS Budget Plan Protects US FDA User Fee Collection

 
• By 

The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.